SCHEMBL4824817

SCHEMBL4824817

CC(=O)N1[C]CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11041079 0.78
SCHEMBL7578302 0.74 ALDH1A1 (0.32)
SCHEMBL23106 0.62
SCHEMBL1206984 0.62
SCHEMBL18228339 0.60 TDP1 (0.57)
SCHEMBL896298 0.60
SCHEMBL8053 0.60
SCHEMBL138527 0.60
SCHEMBL60330 0.60 TDP1 (0.57)
SCHEMBL17901788 0.60 TDP1 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204473-A1 COMPOUND AS IRAK INHIBITOR WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2022-06-30 US claimed
EP-3889150-A1 COMPOUND SERVING AS IRAK INHIBITOR Shanghai Meiyue Biotech Development Co., Ltd. (CN) 2021-10-06 EP claimed
CN-113227079-A Compound as IRAK inhibitor 上海美悦生物科技发展有限公司 2021-08-06 CN claimed
CN-113227079-B Compound as IRAK inhibitor 上海美悦生物科技发展有限公司 2024-06-04 CN disclosed
US-20220204473-A1 COMPOUND AS IRAK INHIBITOR WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2022-06-30 US disclosed
EP-3889150-A1 COMPOUND SERVING AS IRAK INHIBITOR Shanghai Meiyue Biotech Development Co., Ltd. (CN) 2021-10-06 EP disclosed
CN-113227079-A Compound as IRAK inhibitor 上海美悦生物科技发展有限公司 2021-08-06 CN disclosed
US-20080125455-A1 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands VERNALIS RESEARCH LIMITED 2008-05-29 US disclosed
US-20080114018-A1 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands VERNALIS RESEARCH LIMITED 2008-05-15 US disclosed
US-20080090858-A1 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands VERNALIS RESEARCH LIMITED 2008-04-17 US disclosed
US-7323486-B2 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands VERNALIS RESEARCH LIMITED (GB) 2008-01-29 US disclosed
US-7166632-B2 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands VERNALIS RESEARCH LIMITED (GB) 2007-01-23 US disclosed
US-7166613-B2 Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands VERNALIS RESEARCH LIMITED (GB) 2007-01-23 US disclosed
US-6962939-B1 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands VERNALIS RESEARCH LIMITED (GB) 2005-11-08 US disclosed
EP-1202964-B1 CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS VERNALIS RES LTD (GB) 2005-10-12 EP disclosed
US-20050197380-A1 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands VERNALIS RESEARCH LIMITED 2005-09-08 US disclosed
US-20050192334-A1 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands VERNALIS RESEARCH LIMITED 2005-09-01 US disclosed
US-20050187282-A1 Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands VERNALIS RESEARCH LIMITED 2005-08-25 US disclosed
EP-1202964-A1 CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2002-05-08 EP disclosed
WO-2001012602-A1 CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-02-22 WO disclosed